Finanzwire Finanzwire
Basculer en Français
10651 Companies
226542 Keywords
155028 Articles
119935 Press releases
Headlines Articles Press releases AndzonBio2 Remove
  1. Home
  2. Companies
  3. AndzonBio2
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 05/13/2026 at 09:25, 1 month 14 days ago

    AndzonBio2, University of Cambridge, and Cambridge Enterprise Collaborate on Neuroinflammation Therapeutics

    Drug Discovery Collaboration Neurodegenerative Diseases Therapeutic Development Neuroinflammation
  • PRESS RELEASE

    published on 05/13/2026 at 09:20, 1 month 14 days ago

    AndzonBio2, the ALBORADA Drug Discovery Institute at the University of Cambridge and Cambridge Enterprise Announce a Collaboration to Develop First-in-Class Therapeutics for Neuroinflammation

    AndzonBio2 partners with ALBORADA Drug Discovery Institute and Cambridge Enterprise to develop innovative neuroinflammation therapeutics, targeting neurodegenerative diseases like Parkinson's and Alzheimer's
    Therapeutics Neuroinflammation AndzonBio2 ALBORADA Drug Discovery Institute Cambridge Enterprise
    Logo of AndzonBio2
Accesswire
  • Published on 06/27/2026 at 01:40, 11 hours 24 minutes ago

    Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting

  • Published on 06/27/2026 at 00:00, 13 hours 4 minutes ago

    Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010

  • Published on 06/26/2026 at 23:00, 14 hours 4 minutes ago

    Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting

  • Published on 06/26/2026 at 22:50, 14 hours 14 minutes ago

    Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada

  • Published on 06/26/2026 at 22:15, 14 hours 49 minutes ago

    Revive Therapeutics Announces Proposed Private Placement

View all ACCESSWIRE
EQS Group
  • Published on 06/27/2026 at 00:05, 12 hours 59 minutes ago

    EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss

  • Published on 06/27/2026 at 00:04, 13 hours ago

    Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering

  • Published on 06/26/2026 at 23:36, 13 hours 28 minutes ago

    Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering

  • Published on 06/26/2026 at 23:36, 13 hours 28 minutes ago

    EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share

  • Published on 06/26/2026 at 23:27, 13 hours 37 minutes ago

    EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE

View all EQS
Les Echos
  • Published on 06/26/2026 at 17:45, 19 hours 19 minutes ago

    Combined General Meeting, June 25, 2026

  • Published on 06/26/2026 at 14:44, 22 hours 20 minutes ago

    Safran information

  • Published on 06/26/2026 at 07:00, 1 day 6 hours ago

    Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel

  • Published on 06/25/2026 at 17:50, 1 day 19 hours ago

    DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

  • Published on 06/25/2026 at 07:30, 2 days 5 hours ago

    Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy